Floatz logo

Abemaciclib

BRCA2 Gene Mutation

University of California, DavisSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the BRCA2 Gene Mutation cohort.

Asset / SponsorPhaseRating
Olaparib
M.D. Anderson Cancer Center
Phase 3BB
Niraparib
Qian Qin
Phase 3BB
Carboplatin
University of Washington
Phase 2BB
Rucaparib
University of Washington
Phase 2B
Durvalumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2B

View all 14 →

Same molecule, other indications

Abemaciclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Hormone Receptor Positive TumorDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →